An Update on Therapies for Proliferative Lupus Nephritis: How Certain Can We Be About the Evidence?
作者信息
Bomback Andrew S
机构信息
Division of Nephrology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY.
出版信息
Am J Kidney Dis. 2018 Nov;72(5):758-760. doi: 10.1053/j.ajkd.2018.07.007.
Abstract
摘要
相似文献
1
An Update on Therapies for Proliferative Lupus Nephritis: How Certain Can We Be About the Evidence?增殖性狼疮性肾炎治疗的最新进展：我们对证据的确定程度如何？
Am J Kidney Dis. 2018 Nov;72(5):758-760. doi: 10.1053/j.ajkd.2018.07.007.
2
Immunosuppressive Treatment for Proliferative Lupus Nephritis: Summary of a Cochrane Review.增殖性狼疮性肾炎的免疫抑制治疗：Cochrane系统评价总结
Am J Kidney Dis. 2018 Nov;72(5):756-757. doi: 10.1053/j.ajkd.2018.07.008.
3
Long-term outcomes with multi-targeted immunosuppressive protocol in children with severe proliferative lupus nephritis.多靶点免疫抑制方案治疗儿童重症增殖性狼疮性肾炎的长期疗效
Lupus. 2016 Apr;25(4):399-406. doi: 10.1177/0961203315615220. Epub 2015 Nov 3.
4
Multitarget therapy of lupus nephritis: base hit or home run?狼疮性肾炎的多靶点治疗：一垒安打还是全垒打？
J Am Soc Nephrol. 2008 Oct;19(10):1842-4. doi: 10.1681/ASN.2008070779. Epub 2008 Aug 27.
5
6
Predictive factors for low rate of remission in a population of Colombian patients with severe proliferative lupus nephritis.哥伦比亚重症增殖性狼疮性肾炎患者群体中缓解率低的预测因素。
Clin Rheumatol. 2015 May;34(5):897-903. doi: 10.1007/s10067-015-2864-7. Epub 2015 Jan 17.
7
Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis.在接受霉酚酸酯治疗的膜性狼疮性肾炎患者中，使用羟氯喹可预测12个月内完全肾脏缓解。
Lupus. 2006;15(6):366-70. doi: 10.1191/0961203306lu2313oa.
8
Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis.脉冲静脉注射环磷酰胺与霉酚酸酯治疗增殖性狼疮性肾炎诱导疗法的随机对照试验
Nephrology (Carlton). 2005 Oct;10(5):504-10. doi: 10.1111/j.1440-1797.2005.00444.x.
9
Connective tissue diseases: Management of lupus nephritis-new guidelines revealed.结缔组织病：狼疮肾炎的管理——新指南公布。
Nat Rev Rheumatol. 2012 Oct;8(10):565-6. doi: 10.1038/nrrheum.2012.131. Epub 2012 Jul 31.
10
Comparison of disease activity between tacrolimus and mycophenolate mofetil in lupus nephritis: a randomized controlled trial.他克莫司与霉酚酸酯治疗狼疮性肾炎疾病活动度的比较：一项随机对照试验。
Lupus. 2018 Apr;27(4):647-656. doi: 10.1177/0961203317739131. Epub 2017 Nov 6.
引用本文的文献
1
Machine learning models predicts risk of proliferative lupus nephritis.机器学习模型预测增生性狼疮肾炎的风险。
Front Immunol. 2024 Jun 11;15:1413569. doi: 10.3389/fimmu.2024.1413569. eCollection 2024.
2
Searching for a prognostic index in lupus nephritis.狼疮性肾炎的预后指标探索。
Eur J Med Res. 2023 Jan 11;28(1):19. doi: 10.1186/s40001-022-00946-y.
3
Elevated soluble CD163 predicts renal function deterioration in lupus nephritis: a cohort study in Eastern China.可溶性 CD163 水平升高可预测狼疮肾炎患者肾功能恶化：一项来自中国东部的队列研究。
J Int Med Res. 2021 Nov;49(11):3000605211049963. doi: 10.1177/03000605211049963.
4
Analysis of clinical and laboratory characteristics and pathology of lupus nephritis-based on 710 renal biopsies in China.基于中国710例肾活检的狼疮性肾炎临床、实验室特征及病理分析
Clin Rheumatol. 2020 Nov;39(11):3353-3363. doi: 10.1007/s10067-020-05115-2. Epub 2020 May 20.
5
Association of Urine sCD163 With Proliferative Lupus Nephritis, Fibrinoid Necrosis, Cellular Crescents and Intrarenal M2 Macrophages.尿液 sCD163 与增生性狼疮肾炎、纤维素样坏死、细胞性新月体及肾内 M2 巨噬细胞的关系。
Front Immunol. 2020 Apr 15;11:671. doi: 10.3389/fimmu.2020.00671. eCollection 2020.
本文引用的文献
1
Immunosuppressive Treatment for Proliferative Lupus Nephritis: Summary of a Cochrane Review.增殖性狼疮性肾炎的免疫抑制治疗：Cochrane系统评价总结
Am J Kidney Dis. 2018 Nov;72(5):756-757. doi: 10.1053/j.ajkd.2018.07.008.
2
Immunosuppressive treatment for proliferative lupus nephritis.增殖性狼疮性肾炎的免疫抑制治疗
Cochrane Database Syst Rev. 2018 Jun 29;6(6):CD002922. doi: 10.1002/14651858.CD002922.pub4.
3
Induction and Maintenance Immunosuppression Treatment of Proliferative Lupus Nephritis: A Network Meta-analysis of Randomized Trials.增生性狼疮肾炎诱导和维持免疫抑制治疗：随机试验的网络荟萃分析。
Am J Kidney Dis. 2017 Sep;70(3):324-336. doi: 10.1053/j.ajkd.2016.12.008. Epub 2017 Feb 21.
4
Multitarget therapy for induction treatment of lupus nephritis: a randomized trial.狼疮肾炎诱导治疗的多靶点治疗：一项随机试验。
Ann Intern Med. 2015 Jan 6;162(1):18-26. doi: 10.7326/M14-1030.
5
Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study.阿巴西普治疗狼疮肾炎的疗效和安全性：一项为期 12 个月、随机、双盲研究。
Arthritis Rheumatol. 2014 Feb;66(2):379-89. doi: 10.1002/art.38260.
6
The value of repeat kidney biopsy in quiescent Argentinian lupus nephritis patients.重复肾活检在阿根廷静止期狼疮性肾炎患者中的价值。
Lupus. 2014 Jul;23(8):840-7. doi: 10.1177/0961203313518625. Epub 2014 Jan 8.
7
Treatment for lupus nephritis.狼疮性肾炎的治疗。
Cochrane Database Syst Rev. 2012 Dec 12;12:CD002922. doi: 10.1002/14651858.CD002922.pub3.
8
Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study.利妥昔单抗治疗活动性增殖性狼疮性肾炎患者的疗效和安全性：利妥昔单抗狼疮性肾炎评估研究
Arthritis Rheum. 2012 Apr;64(4):1215-26. doi: 10.1002/art.34359. Epub 2012 Jan 9.
9
Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis.霉酚酸酯与硫唑嘌呤作为狼疮性肾炎维持治疗的比较。
N Engl J Med. 2011 Nov 17;365(20):1886-95. doi: 10.1056/NEJMoa1014460.
10
Updates on the treatment of lupus nephritis.狼疮肾炎治疗的新进展。
J Am Soc Nephrol. 2010 Dec;21(12):2028-35. doi: 10.1681/ASN.2010050472. Epub 2010 Nov 4.
Zotero 插件